好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Relationship between Microglial Microvesicles and MRI Metrics in Probable Alzheimer's Disease Patients
Aging and Dementia
IN9 - (-)
006
Astrocytosis and microgliosis are known contributors to neurodegeneration in AD. MMVs represent a novel marker of microglial activation.
CSF, and T1-weighted and DT MRI scans were obtained from 31 probable AD patients (mean age at the MRI 69卤7 years; mean disease duration 4卤2 years; mean Clinical Dementia Rating scale-Sum of Boxes 5卤2). CSF was analyzed by flow cytometry to detect MMVs. Hippocampal volumes were obtained using an automatic approach (FIRST in FSL). The association between hippocampal volume and the MMV level was estimated using the Pearson's coefficient. Tract-based spatial statistic (TBSS) was used to perform a voxel-wise regression analysis investigating the relationship between WM fractional anisotropy (FA) and the number of MMVs.
In probable AD patients, the level of MMVs significantly correlated with the hippocampal volumes (r=-0.51, p=0.005, for both right and left hippocampal volumes). In addition, TBSS showed a negative correlation between the number of MMVs and the FA values of the hippocampal part of the cingulum bundle, bilaterally.
This study shows that the level of MMVs in the CSF of probable AD patients is associated with damage to the gray matter and WM structures of the medial temporal lobe. These findings suggest a greater vulnerability to microglial activation in those regions typically hit by AD.
Authors/Disclosures

PRESENTER 		No disclosure on file
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
Takeshi Sakata Takeshi Sakata has received personal compensation for serving as an employee of Mitsubishi Tanabe.
Dacia Dalla Libera, MD (San Raffaele Hospital) No disclosure on file
Elisa Canu (Ospedale San Raffaele) The institution of Elisa Canu has received research support from Italian Ministry of Health .
Giuseppe Magnani Giuseppe Magnani has nothing to disclose.
No disclosure on file
Andrea Falini No disclosure on file
Giancarlo Comi, MD (University Vita-Salute) Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aspen Healthcare. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Rewind.
Roberto Furlan Roberto Furlan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Roberto Furlan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Roberto Furlan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Roberto Furlan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Roberto Furlan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Roberto Furlan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.